Evidence map›Paper›PMID 42599325›Full record

ArticleWorld journal of urology2026

Deep learning-based automated identification of papillary bladder cancer from endoscopic still images using SE-ResNeXt-50.

Yuto Matsushita, Ayumi Tamura, Tatsuya Masuda, Osamu Hasegawa, Takashi Kodama, Shinya Watanabe, Kyohei Watanabe, Hiromitsu Watanabe, Keita Tamura, Ayana Takemura and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yuto MatsushitaDepartment of Urology, Chutoen General Medical Center, Kakegawa, Shizuoka, Japan.
Ayumi TamuraLogic Corporation, Hamamatsu, Shizuoka, Japan.
Tatsuya MasudaLogic Corporation, Hamamatsu, Shizuoka, Japan.
Osamu HasegawaLogic Corporation, Hamamatsu, Shizuoka, Japan.
Takashi KodamaDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan.
Shinya WatanabeDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan.
Kyohei WatanabeDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan.
Hiromitsu WatanabeDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan.
Keita TamuraDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan.
Ayana TakemuraDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan.
Shunsuke WatanabeDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan.
Daisuke MotoyamaDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan.
Teruo InamotoDepartment of Urology, Hamamatsu University School of Medicine (HUSM), 1-20-1 Handayama, Chuo-Ku, Hamamatsu City, Shizuoka, 431-3192, Japan. t-ina1@hama-med.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer remains a major global health challenge, necessitating rigorous endoscopic surveillance and the precise identification of neoplastic lesions. While the detection of overt tumors is routine, achieving high specificity and distinguishing borderline tumor structures are critical for optimal clinical decision-making. This is especially vital given the rapid evolution of intravesical therapies for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Recent clinical advancements with novel agents-such as gemcitabine-releasing intravesical systems (TAR-200), nadofaragene firadenovec, and the IL-15 superagonist complex (N-803)-fundamentally require a clinically "tumor-free" state through complete resection to ensure maximum therapeutic efficacy. This study presents an advanced artificial intelligence (AI) system developed, utilizing a SE-ResNeXt-50 architecture to automate the classification of papillary bladder tumors from cystoscopic still images. To ensure transparency, Grad-CAM analysis was employed, revealing that the model prioritizes key morphological tumor features. Although background artifacts like air bubbles or mesh-like structures occasionally influence the signal, the system maintains high diagnostic reliability. Our findings suggest that this deep learning framework provides robust decision support, facilitating the rigorous complete resection necessary for successful intervention with next-generation intravesical agents.

Indexed as

Carcinoma, PapillaryCystoscopyDeep LearningUrinary Bladder NeoplasmsHumansNon-Muscle Invasive Bladder Neoplasms

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.